UCB Japan Co and First Third Co Pharmaceuticals jointly announce Vimpat ® intravenous 200mg has been launched in Japan

recently, the BelgianPharmaceutical(http://giant UCB Japan sub-
company(http://UCB Japan Co and First Third Pharmaceuticals announced that Vimpat ® intravenous infusion 200mg (generic name: lacosamide, lacamide) has been listed in Japanabout Vimpat®
Vimpat ® intravenous infusion 200mg is a new dosage form, developed as an alternative to Vimpat oral preparations for the treatment of partial seizure saclics (accompanied or not secondary systemic seizures) in patients with epilepsy who are temporarily unsuitable for oral administrationTherefore, this intravenous fluid dosage is helpful for the ongoing treatment of epilepsy patientsIn mid-March, 10% of vimpatimpat ® dry syrup is also available in Japan, a new dosage form for Vimpat ® tablets 50mg and 100mg, suitable for the treatment of partial seizure seclampsia (accompanied by or unpartnered systemic seizures) in patients with epilepsyVimpat ® 10% of the dry syrup added to the water and mixed before the drug is administered, and is expected to improve medication compliance in patients who have difficulty swallowing Vimpat ® tablets, such as children and elderly patients with impaired swallowing functionVimpat is a new type of NMDA receptor glycine site binding antagonists, belonging to a new class of functional amino acids, is a new dual mechanism of anticonvulsiondrug(http://Compared with other anti-epileptic drugs, Vimpat has the activity of regulating sodium ion channels, sodium ion channels in regulating nervous system activity, promoting the conduction between nerve cells has a very important function, by reducing the hyperactivity of sodium ion channels can control the activity of nerve cells to treat epilepsyVimpat is currently on the marketproducts(http://form includes a variety of tablets, oral syrups, injections, dry syrupsVimpat injections are an alternative form of dosage in patients who are temporarily unable to take it orally